Health knowledge and news provided by doctors.

Newly Diagnosed Patients Do Not Receive Drug Treatment Immediately

Armen Hareyan's picture

Newly Diagnosed Patients

Almost 65% of newly diagnosed patients do not receive drug treatment in the first 360 days of their diagnosis.

"We believe that physicians are prescribing lifestyle modifications such as diet and exercise to the majority of these patients before initiating drug treatment," said Jeremy Goldman, M.D., analyst at Decision Resources. "This level of non-pharmacological treatment is contrary to the advice of thought leaders who only recommend a trial of two to three months with lifestyle interventions."

The report entitled Treatment Algorithms in Hypertension also reveals that surveyed physicians consider beta blockers to be effective in lowering the risk of the cardiovascular complications of hypertension. Seventy-three percent of primary care physicians (PCPs) and 81% of cardiologists consider this benefit a reason for choosing AstraZeneca's Toprol XL over Pfizer's Norvasc. Beta blockers are currently prescribed in 24.3 percent of new patients compared to only 9.9 percent of new patients who are prescribed a calcium-channel blocker

Decision Resources combines in-depth primary research with the most extensive claims-based longitudinal patient-level data from PharMetrics(R) to provide exceptional insight into physicians' prescribing trends and the factors that drive therapy product choice, from diagnosis through multiple courses of treatment, for a specific disease.

For each disease examined, Decision Resources' Treatment Algorithms Insight Series provides:

Follow eMaxHealth on YouTube, Twitter and Facebook.
Please, click to subscribe to our Youtube Channel to be notified about upcoming health and food tips.

-- Summary of U.S. medical practice based on interviews with leading experts in the field

-- Qualitative diagnosis/referral/treatment algorithm for the United States

-- Drug usage by lines of therapy (1st, 2nd, 3rd line)

-- Discussion of key freeform combinations by lines of therapy

-- Product share (class and specific compound level) within each line of therapy (1st, 2nd, 3rd line)

-- Progression of therapy from key 1st line products

-- Pathway to key therapies from previous therapies

-- Qualitative analysis of 2-year forecast incorporating upcoming launches, changes in reimbursement, etc.